Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data

The treatment options for Fabry disease (FD) are enzyme replacement therapy (ERT) with agalsidase alfa or beta, and the oral pharmacological chaperone migalastat. Since few data are available on the effects of switching from ERT to migalastat, we performed a single-center observational study on seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Eleonora, Zanfardino, Mario, Ferreri, Lucia, Santoro, Ciro, Cocozza, Sirio, Capuano, Ivana, Imbriaco, Massimo, Feriozzi, Sandro, Pisani, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784987/
https://www.ncbi.nlm.nih.gov/pubmed/32647377
http://dx.doi.org/10.1038/s41431-020-0677-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784987/
https://www.ncbi.nlm.nih.gov/pubmed/32647377
http://dx.doi.org/10.1038/s41431-020-0677-x

Ejemplares similares